No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
HRTX240517C500
- 2.02
- 0.000.00%
15min DelayTrading Apr 3 09:39 ET
0.00High0.00Low
0.00Open2.02Pre Close0 Volume0 Open Interest0.50Strike Price0.00Turnover1359.40%IV4.69%PremiumMay 17, 2024Expiry Date2.27Intrinsic Value100Multiplier7DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type0.9677Delta0.0136Gamma1.15Leverage Ratio-0.0269Theta0.0000Rho1.12Eff Leverage0.0003Vega
Intraday
- 5D
- 1D
News
Here's What Analysts Are Forecasting For Heron Therapeutics, Inc. (NASDAQ:HRTX) After Its First-Quarter Results
Heron Therapeutics, Inc. (NASDAQ:HRTX) just released its latest first-quarter results and things are looking bullish. Results overall were solid, with revenues arriving 5.1% better than analyst f
Heron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2024 Earnings Call Transcript
Express News | Needham Reiterates Buy on Heron Therapeutics, Maintains $5 Price Target
Heron Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/08/2024 70.65% Needham → $5 Reiterates Buy → Buy 04/23/2024 104.78% Capital One → $6 Initiates Coverage
Heron Therapeutics Inc (HRTX) Q1 2024 Earnings Call Transcript Highlights: Significant ...
Q1 2024 Heron Therapeutics Inc Earnings Call
Comments
Heron Therapeutics' stock price surge may be positive, but the company's core business performance will decide the sustainability of this turnaround. Lack of profitability and minimal revenue growth could discourage potential investors.
Investors in Heron Therapeutics (NASDAQ:HRTX) From Five Years Ago Are Still Down 88%, Even After 21% Gain This Past Week 1
Heron Therapeutics' projected breakeven and profitability rely on optimistic growth estimates. The company's negative equity, possibly due to accounting methods, raises concerns.
📌Last week’s PDUFAs:
$Heron Therapeutics(HRTX.US$ : Approved 1/23 🎉
⇒ ZYNRELEF
⇒ Postoperative pain
⇒ sNDA
⇒ PDUFA: 01/23/24
$Liquidia(LQDA.US$ : NDA review ongoing 🤔
⇒ YUTREPIA
⇒ PH-ILD
⇒ NDA
⇒ PDUFA: 01/24/24
$Theratechnologies(THTX.US$ : CRL 1/24 🙁
⇒ F8 Formulation of Tesamorelin
⇒ Excess abdominal fat in adults w/ HIV
⇒ sBLA
⇒ PDUFA: 01/22/24
$Sanofi(SNY.US$ & $Regeneron Pharmaceuticals(REGN.US$ : Approved 1/25 🎉
⇒ Dupixent
⇒ Eosinophilic esophagitis (pedia)
⇒ sB...
$Heron Therapeutics(HRTX.US$ : Approved 1/23 🎉
⇒ ZYNRELEF
⇒ Postoperative pain
⇒ sNDA
⇒ PDUFA: 01/23/24
$Liquidia(LQDA.US$ : NDA review ongoing 🤔
⇒ YUTREPIA
⇒ PH-ILD
⇒ NDA
⇒ PDUFA: 01/24/24
$Theratechnologies(THTX.US$ : CRL 1/24 🙁
⇒ F8 Formulation of Tesamorelin
⇒ Excess abdominal fat in adults w/ HIV
⇒ sBLA
⇒ PDUFA: 01/22/24
$Sanofi(SNY.US$ & $Regeneron Pharmaceuticals(REGN.US$ : Approved 1/25 🎉
⇒ Dupixent
⇒ Eosinophilic esophagitis (pedia)
⇒ sB...
12
1
$Heron Therapeutics(HRTX.US$ anything gonna happen here today?
1
1
Read more